Y-mAbs Therapeutics, Inc. - Common Stock (YMAB)
4.9100
-0.0100 (-0.20%)
Y-Mabs Therapeutics Inc. is a biotechnology company focused on discovering and developing innovative antibody therapeutics for the treatment of cancer, particularly in pediatric populations
The company specializes in engineered monoclonal antibodies designed to target specific tumor-associated antigens, leveraging advanced technologies to enhance therapeutic efficacy and safety. Y-Mabs is dedicated to addressing unmet medical needs by advancing its product candidates through clinical trials, with the goal of improving outcomes for patients with various forms of cancer.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · March 13, 2025
Via Benzinga · March 13, 2025

Via Benzinga · March 5, 2025

Via Benzinga · January 7, 2025

Via Benzinga · November 18, 2024

Via Benzinga · November 7, 2024

Via Benzinga · November 22, 2024

Via Benzinga · August 13, 2024

Via Benzinga · March 6, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via Benzinga · February 29, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via Benzinga · October 30, 2024

The company didn't quite meet expectations for either trailing results or full-year guidance.
Via The Motley Fool · August 12, 2024

YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 12, 2024

Via Benzinga · August 12, 2024

Via Benzinga · July 2, 2024

YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.
Via Benzinga · March 1, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Via Benzinga · March 1, 2024

Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance.
Via Benzinga · March 1, 2024

Via Benzinga · March 1, 2024

Via Benzinga · February 29, 2024